Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM Stock Titan
Covered in this story
Analyst targets on Alnylam Pharmaceuticals
- Truist Securities: $161 → $225 by Nov 2027 via GuruFocus
- Bernstein: $165 → $199 by Oct 2027 via GuruFocus
- Freedom Broker: $174 → $350 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ALNY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alnylam Pharmaceuticals →Dalsna Finance is currently tracking 29 stories mentioning Alnylam Pharmaceuticals, the earliest published 6 May 2017.
Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.